Liquidia specializes in innovative therapies for rare and chronic pulmonary conditions. Its lead product, Yutrepia, is an inhaled treprostinil powder used to improve exercise ability in adults with pulmonary arterial hypertension (PAH). By delivering medication directly to the lungs, Liquidia aims to enhance treatment tolerance and patient convenience. This advancement primarily benefits PAH patients seeking a more flexible, effective therapeutic option.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends